BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32332631)

  • 1. Association of hepatocellular carcinoma with thiazolidinediones use: A population-based case-control study.
    Lai SW; Lin CL; Liao KF
    Medicine (Baltimore); 2020 Apr; 99(17):e19833. PubMed ID: 32332631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of thiazolidinediones and risk of hip fracture in old people in a case-control study in Taiwan.
    Lin HF; Liao KF; Chang CM; Lin CL; Lin CH; Lai SW
    Medicine (Baltimore); 2017 Sep; 96(36):e7712. PubMed ID: 28885328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
    Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
    Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
    Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
    Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of oral corticosteroids use on risk of hepatocellular carcinoma in high risk populations.
    Lai SW; Lin CL; Liao KF
    Eur J Intern Med; 2018 Jun; 52():73-77. PubMed ID: 29555406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
    Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC
    Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: A population-based case-control study in Taiwan.
    Liao KF; Lin CL; Lai SW; Chen WC
    Eur J Intern Med; 2016 Jan; 27():76-9. PubMed ID: 26433909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study.
    Chang SS; Hu HY
    BMC Cancer; 2013 Sep; 13():420. PubMed ID: 24041200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes: A case-control study in Taiwan.
    Lai SW; Lin HF; Lin CL; Liao KF
    Medicine (Baltimore); 2016 Aug; 95(31):e4455. PubMed ID: 27495077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High incidence of hepatocellular carcinoma in ESRD patients: caused by high hepatitis rate or 'uremia'? a population-based study.
    Hwang JC; Weng SF; Weng RH
    Jpn J Clin Oncol; 2012 Sep; 42(9):780-6. PubMed ID: 22782961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.
    Kasmari AJ; Welch A; Liu G; Leslie D; McGarrity T; Riley T
    Am J Med; 2017 Jun; 130(6):746.e1-746.e7. PubMed ID: 28109969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
    Arvind A; Memel ZN; Philpotts LL; Zheng H; Corey KE; Simon TG
    Metabolism; 2021 Jul; 120():154780. PubMed ID: 33891949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
    van Dalem J; Driessen JHM; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Brouwers MCGJ
    Hepatology; 2021 Nov; 74(5):2467-2477. PubMed ID: 34129693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
    Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
    Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection.
    Lai MS; Hsieh MS; Chiu YH; Chen TH
    Hepatology; 2006 Jun; 43(6):1295-302. PubMed ID: 16729295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone use and the risk of bladder cancer.
    Kuo HW; Tiao MM; Ho SC; Yang CY
    Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Viral Hepatitis Signifies the Association of Premixed Insulin Analogues with Liver Cancer Risks: A Nationwide Population-Based Study.
    Chiang CH; Kuo CS; Lin WW; Su JH; Chen JD; Huang KC
    Int J Environ Res Public Health; 2019 Jun; 16(12):. PubMed ID: 31200528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone and oral cancer risk in patients with type 2 diabetes.
    Tseng CH
    Oral Oncol; 2014 Feb; 50(2):98-103. PubMed ID: 24239280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System.
    Ramos-Nino ME; MacLean CD; Littenberg B
    BMC Med; 2007 Jun; 5():17. PubMed ID: 17584937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between colorectal cancer and thiazolidinediones administration in a case-control study.
    Liao KF; Lin CL; Lai SW
    Biomedicine (Taipei); 2019 Mar; 9(1):4. PubMed ID: 30794151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.